Loading...

Home
ETF
DWTX

DWTX

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

AI Strategies

AI Stock Picker
Swing Trading
SwingMax Portfolio
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Follow SwingMax Portfolio
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

DWTX News

Dogwood Therapeutics Achieves Milestone in HALT-CINP Trial

Feb 02 2026Newsfilter

Dogwood Therapeutics Raises $12.5 Million to Advance Halneuron® Development

Jan 12 2026Globenewswire

Dogwood Therapeutics Reports Positive Interim Results for Halneuron in Chemotherapy-Induced Neuropathic Pain

Dec 23 2025NASDAQ.COM

Dogwood Therapeutics (DWTX) Releases Interim Analysis of Halneuron Phase 2b Study

Dec 22 2025Yahoo Finance

Dogwood Therapeutics Reports Positive Interim Results for Halneuron®; Top-Line Data Expected Q3 2026

Dec 22 2025Globenewswire

Dogwood Therapeutics Registers 100 Participants in Halneuron Study for Chemotherapy-Induced Pain

Nov 11 2025Yahoo Finance

Dogwood Therapeutics Obtains Exclusive Global, Royalty-Free License for SP16 Development and Commercialization as a Cancer Pain Treatment in All-Stock Deal Highlighting Commitment to Enhancing Cancer Patient Care

Sep 29 2025Newsfilter

Dogwood Obtains License to Develop Serpin Pharma's SP16 IV Formulation

Sep 29 2025NASDAQ.COM

Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial

Aug 07 2025Newsfilter

Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference

Jun 03 2025Newsfilter

HC Wainwright & Co. Upgrades Dogwood Therapeutics to Buy, Announces $10 Price Target

Apr 23 2025Benzinga

Nasdaq Tumbles Over 400 Points; Netflix Posts Upbeat Earnings

Apr 21 2025Benzinga

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

Apr 11 2025Newsfilter

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

Mar 31 2025Newsfilter

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

Mar 18 2025Newsfilter

Maxim Group Remains a Buy on Dogwood Therapeutics (DWTX)

Mar 13 2025Business Insider